Irish drugmaker Allergan scored a major coup in 2019, courtesy of a $63 billion buyout offer from AbbVie. In return, Allergan will be bringing over longtime blockbuster Botox, along with at least one fast-selling med and potentially some question marks in its aesthetics business.
Allergan hit $16.09 billion in net revenue in 2019, likely its last as a separate company. That was about a 1.9% increase from the previous year's haul of $15.79.
Most of that was driven, once again, by Allergan's top-selling Botox, which hit $3.79 billion in sales on the year––a 6% bump from the year before. Juvederm, one of Allergan's two other blockbusters, raked in $1.24 billion, a 6.9% increase on the year. Eye drug Restasis, meanwhile, posted $1.19 billion in sales in 2019, a 5.8% decrease from 2018.
But top growth marks for the year belonged to antipsychotic med Vraylar, which hit $857 million in sales in 2019 at an impressive 76% bump from the year before.